免疫学市场规模、份额和成长分析（按分销管道、疾病和地区划分）—产业预测（2026-2033 年）

预计到 2024 年，免疫学市场规模将达到 1,042 亿美元，到 2025 年将达到 1,168.1 亿美元，到 2033 年将达到 2912.9 亿美元，预测期（2026-2033 年）的复合年增长率为 12.1%。

免疫学市场正经历强劲成长，这主要得益于对包括硬化症、类风湿性关节炎和发炎性肠道疾病在内的各种免疫介导疾病治疗方法需求的不断增长。该领域涵盖了广泛的药物、治疗方法、诊断试剂和研究设备，旨在识别、控製或预防过敏、癌症、自体免疫疾病和感染疾病等疾病。先进的生物技术对于开发旨在调节免疫系统功能的标靶治疗至关重要。该市场的主要组成部分包括疫苗、免疫调节剂和单株抗体。酵素连结免疫吸附ELISA检验)、流式细胞技术和基于聚合酶炼式反应 (PCR) 的技术等诊断工具在评估免疫系统功能和检测各种免疫标记方面发挥重要作用。此外，免疫疗法已成为一种重要的癌症治疗方法，这激发了人们对发现新的治疗标靶的研发兴趣。

免疫学市场驱动因素

全球免疫学市场的主要驱动因素之一是自体免疫疾病和慢性发炎性疾病的日益普遍。全球人口老化和生活方式的改变导致类风湿性关节炎、狼疮和发炎性肠道疾病等疾病显着增加。不断扩大的患者群体需要创新的免疫疗法和生物製药，从而推动了研发投入。此外，人们对免疫系统功能的认识不断提高，以及精准医疗和个人化医疗保健的进步，正在推动治疗方法的改进，从而维持免疫学领域的强劲增长，并改善全球患者的治疗效果。

免疫学市场限制因素

全球免疫学市场面临的主要限制因素之一是免疫疗法研发和生产高成本。这些先进治疗方法通常需要大量的研发投入和严格的监管核准，这可能会限制患者的可及性和负担能力。此外，免疫相关疾病的复杂性需要专业的知识和基础设施，这为中小企业进入市场设置了障碍。另外，潜在的副作用和患者反应的个体差异也会阻碍免疫疗法的广泛应用，并使医疗服务提供者和支付方对支持创新免疫疗法持谨慎态度。

免疫学市场趋势

精准医疗的兴起正在重塑免疫学市场，其推动的个人化治疗策略是根据每个人的基因和分子特征量身定制的。这种转变提高了治疗效果，同时最大限度地减少了副作用，从而提高了医疗专业人员和患者的接受度。基因组学、蛋白质组学和生物标记监测等领域的持续进步，为创新标靶治疗铺平了道路，并推动了对更专业化治疗方法的需求。这一发展与以患者为中心的医疗保健模式的更广泛转变完美契合，凸显了满足每位患者独特需求的个人化医疗保健方法的重要性，最终引领免疫学领域走向更加个性化的未来。

目录

介绍

• 调查目标
• 定义
• 市场覆盖范围

调查方法

• 资讯收集
• 二手和一手资讯来源
• 市场规模预测
• 市场假设与限制

执行摘要

前景
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场动态
  • 司机
  • 机会
  • 抑制因素
  • 任务
• 波特分析

关键市场考察

• 技术分析
• 价值链分析
• 市场生态系统
• 案例研究分析
• 监管环境
• 创新矩阵
• 主要投资分析
• 关键成功因素
• 竞争程度

按药物类别分類的免疫学市场

• 单株抗体
• 免疫抑制剂
• 融合蛋白
• 其他的

按疾病适应症分類的免疫学市场

• 类风湿性关节炎
• 干癣性关节炎
• 斑块型干癣
• 僵直性脊椎炎
• 发炎性肠道疾病
• 防止器官排斥
• 其他的

按分销管道分類的免疫学市场

• 离线频道
  • 医院药房
  • 零售药房
  • 其他的
• 线上管道

免疫学市场规模：按地区划分

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲（MEA）
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争格局

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市占率（2025 年）

主要企业简介

• AbbVie, Inc.（US）
• Janssen Global Services, LLC（US）
• Eli Lilly and Company（US）
• Novartis AG（Switzerland）
• Pfizer Inc.（US）
• Bristol-Myers Squibb Company（US）
• Merck Sharp & Dohme Corp.（US）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Amgen Inc.（US）
• Astellas Pharma Inc.（Japan）
• UCB SA（Belgium）
• Sanofi（France）
• Gilead Sciences, Inc.（US）
• Regeneron Pharmaceuticals, Inc.（US）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Takeda Pharmaceutical Company Limited（Japan）
• Horizon Therapeutics plc（Ireland）
• Aimmune Therapeutics, Inc.（US）
• Celgene Corporation（US）
• Incyte Corporation（US）
• Boehringer Ingelheim GmbH（Germany）
• Abbott Laboratories（US）

Immunology Market size was valued at USD 104.2 Billion in 2024 and is poised to grow from USD 116.81 Billion in 2025 to USD 291.29 Billion by 2033, growing at a CAGR of 12.1% during the forecast period (2026-2033).

The immunology market is experiencing robust growth, propelled by the rising demand for therapies addressing various immune-mediated disorders, including sclerosis, rheumatoid arthritis, and inflammatory bowel disease. This sector encompasses a broad spectrum of medications, treatments, diagnostics, and research instruments aimed at identifying, managing, or preventing conditions such as allergies, cancer, autoimmune diseases, and infections. Advanced biotechnological techniques are pivotal in developing targeted treatments that modify immune system functions. Key components in this market include vaccines, immunomodulators, and monoclonal antibodies. Diagnostic tools, such as ELISA assays, flow cytometry, and PCR-based methods, play a vital role in assessing immune system performance and detecting various immunological markers. Additionally, immunotherapy has emerged as a significant cancer treatment, heightening interest in research aimed at uncovering novel therapeutic targets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Immunology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Immunology Market Segments Analysis

Global Immunology Market is segmented by Drug Class, Disease Indication, Distribution Channel, and region. Based on Drug Class, the market is segmented into Monoclonal Antibody, Immunosuppressants, Fusion Proteins, Others. Based on Disease Indication, the market is segmented into Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Immunology Market

One of the key market drivers for the Global Immunology Market is the increasing prevalence of autoimmune diseases and chronic inflammatory disorders. As the global population ages and lifestyles evolve, there is a noticeable rise in conditions such as rheumatoid arthritis, lupus, and inflammatory bowel disease. This growing patient demographic necessitates innovative immunological therapies and biologics, propelling research and development efforts. Furthermore, heightened awareness of immune system functions, along with advancements in precision medicine and personalized healthcare, are fostering improved treatment options, thus sustaining robust growth in the immunology sector and enhancing patient outcomes worldwide.

Restraints in the Immunology Market

One key market restraint for the global immunology market is the high cost associated with the development and manufacturing of immunological therapies. These advanced treatments often require significant investment in research and development, as well as stringent regulatory approvals, which can limit accessibility and affordability for patients. Additionally, the complex nature of immune-related diseases necessitates specialized expertise and infrastructure, creating barriers for smaller companies to enter the market. This, combined with the potential for adverse effects and the variability in individual patient responses, hampers broader adoption and can lead to hesitance among healthcare providers and payers in supporting innovative immunotherapy solutions.

Market Trends of the Immunology Market

The advent of precision medicine is reshaping the immunology market by fostering personalized treatment strategies tailored to individual genetic and molecular profiles. This transformation enhances therapeutic efficacy while minimizing adverse effects, contributing to its rising acceptance among healthcare professionals and patients alike. Continuous advancements in fields such as genomics, proteomics, and biomarker research are paving the way for innovative targeted therapies, driving demand for more specialized treatments. This evolution aligns seamlessly with the broader shift toward patient-centered care models, emphasizing the importance of individualized approaches in healthcare that cater to the unique needs of each patient, ultimately steering the immunology landscape towards a more tailored future.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Case study Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Immunology Market by Drug Class

• Market Overview
• Monoclonal Antibody
• Immunosuppressants
• Fusion Proteins
• Others

Immunology Market by Disease Indication

• Market Overview
• Rheumatoid Arthritis
• Psoriatic Arthritis
• Plaque Psoriasis
• Ankylosing Spondylitis
• Inflammatory Bowel Disease
• Prophylaxis of Organ Rejection
• Others

Immunology Market by Distribution Channel

• Market Overview
• Offline Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
• Online Channel

Immunology Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2025

Key Company Profiles

• AbbVie, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Global Services, LLC (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck Sharp & Dohme Corp. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB SA (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Therapeutics plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aimmune Therapeutics, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments